This is a demo store. No orders will be fulfilled.

首页   400-620-6333
  • 登录
  • 注册
  • 英文站
切换导航
我的购物车
搜索
高级搜索
菜单
登录
设置
྾

亚叶酸钙盐水合物

COA COA
    级别和纯度:
  • ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
F107310-250mg
 250mg 期货 Stock Image
F107310-1g
 1g 现货 Stock Image
F107310-5g
 5g 现货 Stock Image
F107310-25g
 25g 现货 Stock Image
大包装询价 收藏夹 比较  SDS下载  DATASHEET  质量标准
查看相关系列
Antifolate (40) Cell Cycle (7376) Cell Cycle/DNA Damage (2603) Endogenous Metabolite (978) Metabolic Enzyme/Protease (4889) 代谢物 (8911) 六元杂环化合物 (1701) 嘧啶类 (742)
main product photo

基本描述

别名 亚叶酸钙 | 叶素钙 | 5-甲酰基-5,6,7,8-四氢蝶酰基-L-谷氨酸 钙盐 | 叶醛酸钙 | 嗜橙菌因子 钙盐 | 甲酰四氢叶酸 钙盐 | 5-甲酰基-5,6,7,8-四氢叶酸 钙盐
英文别名 AMPHOTERICIN B (USP-RS) | Calcii folinas | BUDESONIDE COMPONENT OF BREZTRI | Calcifolin | Folinac | Leucovorin calcium salt | UNII-RPR1R4C0P4 | Calinat | Folaren | Wellcovorin | Anhydrous calcium folinate | Glutamic acid, N-(p-(((2-amino-5-formyl-5,6,7,8-
规格或纯度 ≥98%
英文名称 Folinic acid calcium salt hydrate
应用 亚叶酸钙抵消叶酸拮抗剂的效果，叶酸拮抗剂是靠结合叶酸脱氢还原酶（dihydrofolate reductase），从而阻止叶酸转换成四氢叶酸。医学上，在甲氨喋呤化疗后，亚叶酸钙用于减少甲氨喋呤的毒性。亚叶酸钙也在抗癌方面增强5-氟尿嘧啶的细胞毒性效果。
储存温度 避光,充氩
运输条件 常规运输
产品介绍

亚叶酸钙抵消叶酸拮抗剂的效果，叶酸拮抗剂是靠结合叶酸脱氢还原酶（dihydrofolate reductase），从而阻止叶酸转换成四氢叶酸。医学上，在甲氨喋呤化疗后，亚叶酸钙用于减少甲氨喋呤的毒性。亚叶酸钙也在抗癌方面增强5-氟尿嘧啶的细胞毒性效果。
纯度 ≥98%

关联靶点（人）

Homo sapiens (32628 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
A498 (42825 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CAKI-1 (44928 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
CCRF-CEM (65223 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
COLO 205 (50209 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
DLD-1 (17511 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
DMS-273 (14108 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HL-60 (67320 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HT-29 (80576 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
K562 (73714 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
KM12 (47707 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
MCF7 (126967 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
MOLT-4 (49676 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OVCAR-3 (48710 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OVCAR-4 (44535 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OVCAR-5 (45555 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
OVCAR-8 (47708 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
RPMI-8226 (44974 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
RXF 393 (41971 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SF-295 (48000 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SK-MEL-2 (46422 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SK-MEL-28 (48833 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SK-MEL-5 (47095 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SK-OV-3 (52876 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SN12C (47755 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SNB-19 (46794 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SNB-78 (14240 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
U-251 (51189 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
UACC-257 (46019 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
UACC-62 (47335 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
UO-31 (46270 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
XF498 (12972 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
A549 (127892 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
NCI/ADR-RES (33767 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
EKVX (44102 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
NCI-H322M (45589 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HCC 2998 (41480 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HCT-116 (91556 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HOP-18 (11577 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HOP-92 (41141 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
NCI-H460 (60772 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SF-268 (49410 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
IGROV-1 (47897 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
KM-20L2 (14967 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
LOX IMVI (44321 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
HOP-62 (47048 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
M19-MEL (15326 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Malme-3M (44254 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SNB-75 (44215 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
NCI-H226 (44470 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

关联靶点（其它种属）

P388 (20296 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
P388/ADR (1216 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

PubChem SID 504773265
分子类型 小分子
IIUPAC Name calcium;(2S)-2-[[4-[(2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioate
INCHI 1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1
InChi Key KVUAALJSMIVURS-ZEDZUCNESA-L
Smiles [Ca++].[H]O[H].[H]C(=O)N1C(CNc2ccc(cc2)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)CNc3nc(N)nc(O)c13
Isomeric SMILES C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Ca+2]
分子量 511.50 (anhydrous basis)
Reaxy-Rn 5723924
Reaxys-RN link address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5723924&ln=

化学和物理性质

溶解性 可溶于水；不溶于乙醇
密度 1.223
敏感性 对光线敏感，易吸潮
熔点 195°C
分子量 511.500 g/mol
XLogP3
氢键供体数Hydrogen Bond Donor Count 5
氢键受体数Hydrogen Bond Acceptor Count 10
可旋转键计数Rotatable Bond Count 7
精确质量Exact Mass 511.113 Da
单同位素质量Monoisotopic Mass 511.113 Da
拓扑极表面积Topological Polar Surface Area 221.000 Ų
重原子数Heavy Atom Count 35
形式电荷Formal Charge 0
复杂度Complexity 900.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 1
未定义的原子立体中心计数Undefined Atom Stereocenter Count 1
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 2

安全和危险性（GHS）

象形图 GHS07,   GHS08
信号词 危险
危险声明

H315: 引起皮肤刺激

H317: 可能引起皮肤过敏反应

H319: 引起严重眼睛刺激

H334: 吸入可能引起过敏或哮喘病症状或呼吸困难

H335: 可能引起呼吸道刺激
预防措施声明

P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾

P264: 处理后要彻底洗手。

P271: 仅在室外或通风良好的地方使用。

P272: 被污染的工作服不允许离开工作场所

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P284: 如果通风不良，请佩戴呼吸防护装置。

P321: 特殊处理（请参阅此标签上的...）。

P302+P352: 如皮肤沾染：用水充分清洗。

P304+P340: 如误吸入：将人转移到空气新鲜处，保持呼吸舒适体位。

P305+P351+P338: 如进入眼睛：用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出，取出隐形眼镜。继续冲洗。

P333+P313: 如发生皮肤刺激或皮疹：求医/就诊。

P362+P364: 脱掉沾污的衣服，清洗后方可重新使用。

P405: 密闭存放

P403+P233: 存放在通风良好的地方。保持容器密闭。

P501: 将内容物/容器处理到。。。

P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。

P337+P317: 如果眼睛刺激持续：寻求医疗帮助。

P332+P317: 如果出现皮肤刺激：请寻求医疗帮助。

P319: 如果你感到不适，请寻求医疗帮助。

P342+P316: 如果出现呼吸道症状：立即寻求急救。
RTECS MA0600500

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到15个结果

批号(Lot Number) 证书类型 货号
B2527406 分析证书 F107310
B2527407 分析证书 F107310
G2403342 分析证书 F107310
G2403343 分析证书 F107310
K2408116 分析证书 F107310
B2513051 分析证书 F107310
A2426122 分析证书 F107310
A2426123 分析证书 F107310
A2426131 分析证书 F107310
A2426133 分析证书 F107310
A2426132 分析证书 F107310
D2418076 分析证书 F107310
C23101264 分析证书 F107310
D2318559 分析证书 F107310
D2318954 分析证书 F107310

显示更多⌵

可替换产品

  1. 亚叶酸钙盐水合物
    亚叶酸钙盐水合物
    • 10mM in Water

    ¥205.90

引用文献

1. I E Smith.  (1999-08-12)  Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer..  Oncology (Williston Park, N.Y.),  13  ((7 Suppl 3)): (82-85).  [PMID:10442370]
2. Louis-Charles Moreau,Raghu Rajan,Michael P Thirlwell,Thierry Alcindor.  (2013-04-09)  Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting..  Anticancer research,  33  ((4)): (1765-1768).  [PMID:23564831]
3. Le-Chi Ye,Tian-Shu Liu,Li Ren,Ye Wei,De-Xiang Zhu,Sheng-Yong Zai,Qing-Hai Ye,Yiyi Yu,Bo Xu,Xin-Yu Qin,Jianmin Xu.  (2013-04-10)  Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  31  ((16)): (1931-1938).  [PMID:23569301]
4. Esther Bonda-Shkedi,Myriam Weyl Ben Arush,Chaim Kaplinsky,Shifra Ash,Yaakov Goshen,Isaac Yaniv,Ian J Cohen.  (2013-04-25)  The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study..  Journal of pediatric hematology/oncology,  35  ((4)): (271-275).  [PMID:23612378]
5. Agnieszka Karbownik,Edyta Szałek,Hanna Urjasz,Malwina Kadziołka,Edmund Grześkowiak.  (2013-04-26)  Stability of calcium folinate (Teva) in concentrate after re-use and in dilute infusions in 0.9% NaCl in polyethylene bags..  Acta poloniae pharmaceutica,  70  ((2)): (301-307).  [PMID:23614286]
6. Gakuji Osawa,Kazuhiko Yoshimatsu,Hajime Yokomizo,Sachiyo Okayama,Masano Sagawa,Yoshihiko Naritaka.  (2013-05-15)  Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography..  Cancer chemotherapy and pharmacology,  72  ((1)): (209-215).  [PMID:23670642]
7. F Loupakis,M Schirripa,C Caparello,N Funel,L Pollina,E Vasile,C Cremolini,L Salvatore,M Morvillo,C Antoniotti,F Marmorino,G Masi,A Falcone.  (2013-05-25)  Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab..  British journal of cancer,  108  ((12)): (2549-2556).  [PMID:23703247]
8. S Gillianne DeFoe,Peyman Kabolizadeh,Dwight E Heron,Sushil Beriwal.  (2013-06-06)  Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy..  Oncology,  85  ((1)): (1-7).  [PMID:23736101]
9. Terence C Chua,Liam E Quinn,Jing Zhao,David L Morris.  (2013-06-06)  Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases..  Journal of surgical oncology,  108  ((2)): (81-88).  [PMID:23737041]
10. Joo Won Chung,Hui Won Jang,Moon Jae Chung,Jeong Youp Park,Seung Woo Park,Jae Bock Chung,Si Young Song,Seungmin Bang.  (2013-07-17)  Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer..  Hepato-gastroenterology,  60  ((122)): (363-367).  [PMID:23858557]
11. Kenji Tomizawa,Yutaka Hanaoka,Shigeo Toda,Jin Moriyama,Shuichiro Matoba,Hiroya Kuroyanagi,Masaji Hashimoto,Harushi Udagawa,Goro Watanabe.  (2013-07-19)  [A retrospective study of UFT and oral leucovorin combination adjuvant chemotherapy for patients over 76 years old with stage III colon cancer]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((7)): (881-885).  [PMID:23863728]
12. Genya Hamano,Takashi Ikebe,Katsuyuki Mayumi,Masashi Takemura,Takaaki Hori,Takayoshi Nishioka.  (2013-07-19)  [Successful treatment of a patient using mFOLFOX6 after laparoscopic surgery for rectal cancer with peritoneal dissemination]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((7)): (951-954).  [PMID:23863744]
13. M Wasif Saif,Adam M Lee,Steven M Offer,Kathleen McConnell,Valerie Relias,Robert B Diasio.  (2014-01-07)  A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach..  Mayo Clinic proceedings,  89  ((1)): (131-136).  [PMID:24388031]
14. K Imai,Y Emi,K-I Iyama,T Beppu,Y Ogata,Y Kakeji,H Samura,E Oki,Y Akagi,Y Maehara,H Baba.  (2014-01-07)  Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome..  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,  40  ((5)): (559-566).  [PMID:24388740]
15. Toshiaki Yasui,Hideyo Mukubo,Shinichi Nakanuma,Nariatsu Sato,Ichiro Kita.  (2014-01-08)  [A case of recurrent duodenal carcinoma successfully controlled with FOLFOX treatment]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (1726-1728).  [PMID:24393902]
16. Toshinori Sueda,Shingo Noura,Masayuki Ohue,Tatsushi Shingai,Kunihito Gotoh,Masaaki Motoori,Hidenori Takahashi,Kentaro Kishi,Shigeru Marubashi,Yoshiyuki Fujiwara,Hiroaki Ohigashi,Masahiko Yano,Yasuhiko Tomita,Osamu Ishikawa.  (2014-01-08)  [A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (1965-1967).  [PMID:24393981]
17. Katsunori Ami,Yosuke Kawai,Ryota Seki,Kentaro Gokita,Shoko Takeuchi,Keiichi Fujiya,Jun Takasaki,Hidetoshi Amagasa,Hirotaka Kamikozuru,Hideaki Ganno,Kenichiro Imai,Akira Fukuda,Takeshi Nagahama,Masayuki Ando,Youichi Okada,Shikofumi Tei,Kuniyoshi Arai.  (2014-01-08)  [A case of successful radical resection of rectal cancer with neo-adjuvant chemoradiotherapy]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (1987-1989).  [PMID:24393988]
18. Yasuyo Nakayasu,Kazuhiko Yoshimatsu,Hajime Yokomizo,Gakuji Osawa,Yuki Yano,Mao Nakayama,Akiko Sakuma,Kentaro Yamaguchi,Shunichi Shiozawa,Takeshi Shimakawa,Takao Katsube,Yoshihiko Naritaka.  (2014-01-08)  [Two cases of locally advanced colorectal cancer curatively resected after neoadjuvant chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin plus panitumumab]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (2029-2031).  [PMID:24394002]
19. Hiroshi Kuwabara,Shuichi Watanabe,Bo Liu,Akito Mitsuoka,Takahiro Sanada,Kazumi Nakajima,Narihide Goseki.  (2014-01-08)  [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (2032-2034).  [PMID:24394003]
20. Atsushi Tsuneda,Tohru Kurata,Naoki Makita,Shigeta Hagino,Keiko Iwata,Masato Kiriyama.  (2014-01-08)  [Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (2038-2040).  [PMID:24394005]
21. Pierre Michel,Gilles Breysacher,Françoise Mornex,Jean François Seitz,Denis Pere-Verge,Isabelle Martel-Lafay,Roger Faroux,Sophie Chapet,Iradj Sobhani,Denis Pezet,Thomas Aparicio,Suzanne Nguyen,Bertrand Dousset,Jean-Louis Jouve,Emilie Maillard.  (2014-01-18)  Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308..  European journal of cancer (Oxford, England : 1990),  50  ((6)): (1076-1083).  [PMID:24433843]
22. Chien-Yu Lu,Ching-Wen Huang,Huang-Ming Hu,Hsiang-Lin Tsai,Chun-Ming Huang,Fang-Jung Yu,Ming-Yii Huang,Se-Fen Chang,Meng-Lin Huang,Jaw-Yuan Wang.  (2014-01-28)  Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting..  Translational research : the journal of laboratory and clinical medicine,  164  ((2)): (169-176).  [PMID:24462762]
23. Juan Antonio Cruzado,Sonia López-Santiago,Virginia Martínez-Marín,Gema José-Moreno,Ana Belén Custodio,Jaime Feliu.  (2014-02-19)  Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,  22  ((7)): (1815-1823).  [PMID:24535240]
24. Akira Ooki,Masahiko Ando,Junichi Sakamoto,Atushi Sato,Hirofumi Fujii,Kensei Yamaguchi.  (2014-02-22)  A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial..  Japanese journal of clinical oncology,  44  ((4)): (383-387).  [PMID:24558128]
25. Lee S Schwartzberg,Fernando Rivera,Meinolf Karthaus,Gianpiero Fasola,Jean-Luc Canon,J Randolph Hecht,Hua Yu,Kelly S Oliner,William Y Go.  (2014-04-02)  PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  32  ((21)): (2240-2247).  [PMID:24687833]
26. Klaus Mross,Max Scheulen,Dirk Strumberg,Jan Kuhlmann,Friederike Kanefendt,Fritz Sörgel,Ulrich Jaehde,Iris Burkholder,Berta Moritz,Martin Büchert.  (2014-05-08)  FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data..  International journal of clinical pharmacology and therapeutics,  52  ((8)): (642-652).  [PMID:24800922]
27. Hyuk Hur,Nam Kyu Kim,Byung Soh Min,Seung Hyuk Baik,Kang Young Lee,Woong Sub Koom,Joong Bae Ahn,Hoguen Kim.  (2014-05-14)  Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?.  Diseases of the colon and rectum,  57  ((5)): (592-601).  [PMID:24819099]
28. Hiroshi Tanabe,Tsunenobu Takase,Daishi Morimoto,Yuri Tanaka,Arihiro Shibata,Toyohisa Yaguchi.  (2014-06-12)  [Effective chemotherapy with bevacizumab/FOLFOX4 for neuroendocrine carcinoma of the ascending colon - a case study]..  Gan to kagaku ryoho. Cancer & chemotherapy,  41  ((5)): (661-664).  [PMID:24917018]
29. Marie Chaix,Julie Vincent,Véronique Lorgis,François Ghiringhelli.  (2014-07-12)  FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer..  Oncology,  87  ((3)): (148-158).  [PMID:25012455]
30. Hirofumi Yasui,Kei Muro,Yasuhiro Shimada,Akihito Tsuji,Shinichi Sameshima,Hideo Baba,Taroh Satoh,Tadamichi Denda,Kenji Ina,Tomohiro Nishina,Kensei Yamaguchi,Taito Esaki,Shinya Tokunaga,Hiroyuki Kuwano,Narikazu Boku,Yoshito Komatsu,Masahiko Watanabe,Ichinosuke Hyodo,Satoshi Morita,Kenichi Sugihara.  (2014-08-12)  A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study..  Journal of cancer research and clinical oncology,  141  ((1)): (153-160).  [PMID:25106731]
31. Tetsuro Ikeya,Masatsune Shibutani,Kiyoshi Maeda,Kenji Sugano,Hisashi Nagahara,Hiroshi Ohtani,Kosei Hirakawa.  (2014-08-16)  Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer..  Journal of cancer research and clinical oncology,  141  ((2)): (307-313).  [PMID:25124497]
32. Hua-Nian Zhang,Xue-Lian He,Cheng Wang,Yang Wang,Yu-Jun Chen,Jian-Xin Li,Chang-He Niu,Ping Gao.  (2014-08-19)  Impact of SLCO1B1 521T\u2009>\u2009C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate..  Pediatric blood & cancer,  61  ((12)): (2203-2207).  [PMID:25130190]
33. Noriyasu Chika,Keiichiro Ishibashi,Norimichi Okada,Yusuke Tajima,Kensuke Kumamoto,Yoichi Kumagai,Hiroyuki Baba,Norihiro Haga,Motohiko Sano,Hideyuki Ishida.  (2014-08-19)  [The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older]..  Gan to kagaku ryoho. Cancer & chemotherapy,  41  ((7)): (857-862).  [PMID:25131872]
34. Ahmadur Rahman.  (2014-12-17)  FOLFOXIRI and bevacizumab in metastatic colorectal cancer..  The Lancet. Oncology,  15  ((13)): (e590-e590).  [PMID:25499288]
35. Qing Zhang,Jeremy Tey,Zhe Yang,Ping Li,Lihua Peng,Shen Fu,Guofeng Huang,Fei Xiong,Jiade J Lu.  (2015-01-24)  Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer..  American journal of clinical oncology,  38  ((1)): (11-16).  [PMID:25616201]
36. Annika Urbanek,Matija Popovic,Anna Morató,Alejandro Estaña,Carlos A Elena-Real,Pablo Mier,Aurélie Fournet,Frédéric Allemand,Stephane Delbecq,Miguel A Andrade-Navarro,Juan Cortés,Nathalie Sibille,Pau Bernadó.  (2020-05-14)  Flanking Regions Determine the Structure of the Poly-Glutamine in Huntingtin through Mechanisms Common among Glutamine-Rich Human Proteins..  Structure (London, England : 1993),  28  ((7)): (733-746).  [PMID:32402249]
37. Steven D Forsythe,Shyama Sasikumar,Omeed Moaven,Hemamylammal Sivakumar,Perry Shen,Edward A Levine,Shay Soker,Aleksander Skardal,Konstantinos I Votanopoulos.  (2020-07-08)  Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform..  Annals of surgical oncology,  27  ((13)): (4950-4960).  [PMID:32632882]
38. Pasquale F Innominato,Sylvie Giacchetti,Thierry Moreau,Georg A Bjarnason,Rune Smaaland,Christian Focan,Carlo Garufi,Stefano Iacobelli,Marco Tampellini,Salvatore Tumolo,Carlos Carvalho,Abdoulaye Karaboué,Antoine Poncet,David Spiegel,Francis Lévi.  (2013-05-02)  Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer..  Cancer,  119  ((14)): (2564-2573).  [PMID:23633399]
39. E V Trusilova,N S Besova,S G Bagrova,V A Gorbunova,I S Stilidi,S N Nered.  (2013-07-03)  [Results of combined treatment of patients with metastatic gastric cancer. Case study]..  Voprosy onkologii,  59  ((1)): (123-125).  [PMID:23814839]
40. Nobuhiro Misumi,Takashi Goto,Takanori Miyoshi,Mikako Hiraike,Hiromi Shirasawa,Ooki Saito,Takashi Nishino,Masaharu Oudo.  (2013-07-16)  [Risk factors for hyperammonemia during mFOLFOX6 treatment]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((4)): (483-487).  [PMID:23848016]
41. Yoshiki Sato,Kenji Doden,Yoji Nishida,Satsuki Shimizu,Nobuhiro Tanaka,Daisuke Yagi,Yoshihide Asaumi,Yasumitsu Hirano,Kazuya Maeda,Tamon Miyanaga,Masakazu Hattori,Yasuo Hashizume.  (2013-07-19)  [Bevacizumab therapy for a colorectal cancer patient or hemodialysis with hepatic metastasis]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((5)): (647-650).  [PMID:23863592]
42. Naoto Koike,Yuji Ohshima,Toshiaki Takeuchi,Seiji Arita,Eiji Shinozaki.  (2013-07-19)  [Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((6)): (815-817).  [PMID:23863666]
43. Shao-Shui Chen,Xiao-Chun Yang,Feng Chi,Wen-Zheng Yu,Zhen-Bo Wang,Fang-Ling Ning,Ze-Shun Yu,Yan-Zhang Hao,Mian-Li Li,Feng Wang,Dian-Zhong Geng,Li-Hua Liu,Xin-Jun Dong,Xian-Zhong Peng,Chun-Xiang Ji.  (2013-07-25)  A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma..  Oncology research,  20  ((7)): (327-332).  [PMID:23879173]
44. Jean-Yves Douillard,Kelly S Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Barugel,Yves Humblet,Gyorgy Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocákova,Paul Ruff,Maria Błasińska-Morawiec,Martin Šmakal,Jean Luc Canon,Mark Rother,Richard Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D Patterson.  (2013-09-13)  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer..  The New England journal of medicine,  369  ((11)): (1023-1034).  [PMID:24024839]
45. Minoru Fukuchi,Kohki Kuwabara,Yoshitaka Tsuji,Hiroyuki Baba,Keiichiro Ishibashi,Noriyasu Chika,Satoshi Hatano,Takeaki Matsuzawa,Kensuke Kumamoto,Youichi Kumagai,Erito Mochiki,Hideyuki Ishida.  (2013-11-14)  C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy..  Anticancer research,  33  ((11)): (5051-5055).  [PMID:24222149]
46. Sebastian Stintzing,Heinz-Josef Lenz.  (2013-11-16)  A small cog in a big wheel: PIK3CA mutations in colorectal cancer..  Journal of the National Cancer Institute,  105  ((23)): (1775-1776).  [PMID:24231451]
47. Shuji Ogino,Xiaoyun Liao,Yu Imamura,Mai Yamauchi,Nadine J McCleary,Kimmie Ng,Donna Niedzwiecki,Leonard B Saltz,Robert J Mayer,Renaud Whittom,Alexander Hantel,Al B Benson,Rex B Mowat,Donna Spiegelman,Richard M Goldberg,Monica M Bertagnolli,Jeffrey A Meyerhardt,Charles S Fuchs.  (2013-11-16)  Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial..  Journal of the National Cancer Institute,  105  ((23)): (1789-1798).  [PMID:24231454]
48. Junji Furuse.  (2013-12-07)  [Current status and future directions of chemotherapy for pancreatic cancer]..  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,  110  ((12)): (2060-2065).  [PMID:24305093]
49. Ling-Wei Wang,Chin-Fu Hsiao,William Tzu-Liang Chen,Hao-Hsien Lee,Tzu-Chen Lin,Hung-Chang Chen,Hong-Hwa Chen,Chun-Ru Chien,Tze-Yi Lin,Tsang-Wu Liu.  (2014-01-01)  Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study..  Journal of surgical oncology,  109  ((6)): (580-585).  [PMID:24374744]
50. Hidenori Takahashi,Toshiaki Ishikawa,Noriko Iwata,Hironobu Baba,Taiki Masuda,Satoshi Okazaki,Takatoshi Matsuyama,Megumi Ishiguro,Hirotoshi Kobayashi,Satoru Iida,Hiroyuki Uetake,Kenichi Sugihara.  (2014-01-08)  [A case of advanced rectal cancer treated with leucovorin, fluorouracil, and oxaliplatin plus panitumumab preoperative chemotherapy]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (1953-1955).  [PMID:24393977]
51. Eisuke Ojima,Tatsuo Nakano,Ayako Kanamoto,Shozo Sasaki.  (2014-01-08)  [A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (1962-1964).  [PMID:24393980]
52. Kazuo Wakatsuki,Shigeru Yoshioka,Masayuki Shiobara,Masaaki Kataoka,Shuka Arai,Toru Tonooka,Koutaro Miyazawa,Yoshio Oeda.  (2014-01-08)  [A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy]..  Gan to kagaku ryoho. Cancer & chemotherapy,  40  ((12)): (2026-2028).  [PMID:24394001]
53. Katherine Van Loon,Alan P Venook.  (2014-02-12)  Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  32  ((10)): (991-996).  [PMID:24516031]
54. R T Owen.  (2014-02-14)  Folate augmentation of antidepressant response..  Drugs of today (Barcelona, Spain : 1998),  49  ((12)): (791-798).  [PMID:24524097]
55. Chih-Sheng Huang,Jen-Kou Lin,Ling-Wei Wang,Wen-Yih Liang,Chun-Chi Lin,Yuan-Tzu Lan,Huann-Sheng Wang,Shung-Haur Yang,Jeng-Kai Jiang,Wei-Shone Chen,Tzu-Chen Lin,Shih-Ching Chang.  (2014-02-15)  Assessment of the value of carcinoembryonic antigen reduction ratio as a prognosis factor in rectal cancer..  American journal of surgery,  208  ((1)): (99-105).  [PMID:24524862]
56. Harpreet Wasan,Angela M Meade,Richard Adams,Richard Wilson,Cheryl Pugh,David Fisher,Benjamin Sydes,Ayman Madi,Bruce Sizer,Charles Lowdell,Gary Middleton,Rachel Butler,Richard Kaplan,Tim Maughan.  (2014-04-08)  Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial..  The Lancet. Oncology,  15  ((6)): (631-639).  [PMID:24703531]
57. Shumpei Mukai,Shungo Endo,Kenta Nakahara,Daisuke Takayanagi,Chiyo Maeda,Yusuke Takehara,Tomokatsu Omoto,Yoko Wada,Hiroyuki Kida,Eiji Hidaka,Fumio Ishida,Jun-ichi Tanaka,Shin-ei Kudo.  (2014-04-20)  [A case of severe enteritis induced by adjuvant chemotherapy for colon cancer]..  Gan to kagaku ryoho. Cancer & chemotherapy,  41  ((4)): (499-502).  [PMID:24743369]
58. Tingyu Wu,Zhongchuan Wang,Yun Liu,Zubing Mei,Guanghui Wang,Zhonglin Liang,Ang Cui,Xuguang Hu,Long Cui,Yili Yang,Chen-Ying Liu.  (2014-07-27)  Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8..  Clinical immunology (Orlando, Fla.),  154  ((2)): (116-126).  [PMID:25063444]
59. Fotios Loupakis,Chiara Cremolini,Gianluca Masi,Sara Lonardi,Vittorina Zagonel,Lisa Salvatore,Enrico Cortesi,Gianluca Tomasello,Monica Ronzoni,Rosella Spadi,Alberto Zaniboni,Giuseppe Tonini,Angela Buonadonna,Domenico Amoroso,Silvana Chiara,Chiara Carlomagno,Corrado Boni,Giacomo Allegrini,Luca Boni,Alfredo Falcone.  (2014-10-23)  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer..  The New England journal of medicine,  371  ((17)): (1609-1618).  [PMID:25337750]
60. Alessandro Paniccia,Barish H Edil,Richard D Schulick,Joshua T Byers,Cheryl Meguid,Csaba Gajdos,Martin D McCarter.  (2014-12-17)  Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study..  Medicine,  93  ((27)): (e198-e198).  [PMID:25501072]

溶液计算器

上海阿拉丁生化科技股份有限公司
© 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

上海工商 危险品化学品经营许可证（带存储）营业执照(三证合一)